• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
  • Issues
    • Current Issue
    • Issue Archives
  • Editor's Update
  • Advertise
  • Reprints
  • Authors
    • Author Instructions
    • Submission Portal
  • Reviewers
  • Contact

Search

Venous Laser Updates: New Wavelength or New Fibers?

  • Wed, 3/3/10 - 2:07pm
  • 0 Comments
  • 7142 reads
Start Page: 
77
End Page: 
81
Author(s): 

Lowell S. Kabnick, MD, FACS, FACPh


Introduction

Since the introduction of endovenous lasers (EVL) in the early 2000s, procedure methodologies, as well as device technologies, have evolved extensively in the endeavor to improve treatment outcomes. As each novel parameter has been studied, new data have enabled the venous ablation community to acquire an enhanced understanding of the laser’s mechanism of action. The primary subject matter in EVL studies has routinely included one or a combination of the following: laser fiber vein-wall contact,1,2 linear endovenous energy density (LEED),  3,4 laser power settings,5 variable laser wavelengths,6,7 and most recently, covered laser fibers.8,9 This article aims to provide a succinct review of these major topics, from EVL inception to the latest methodologies employed by thought leaders.

Evolution of EVL Technology

The shift from pulsed energy to continuous laser energy. Initial investigators of endovenous lasers employed methodologies that involved laser fiber vein-wall contact and bare-tip fibers to deliver pulsed energy. Users combined manual compression with a slow pullback of the fiber.1,2,10 At this early juncture, it was believed that the primary mechanism of action for vein obliteration was direct contact with the vessel wall.15 The pulsed method with applied compression produced several perforations at the site of contact of the bare-tip fiber with the vessel wall, resulting in high rates of post-operative pain and bruising.1,2,10–12 Ensuing these early adverse findings, investigators began utilizing continuous energy instead of pulsed energy, and discontinued the use of manual compression.2,10

Other early researchers postulated that laser-induced steam bubble formation, similar to direct fiber-tip contact, caused perforations of adjacent wall areas.11,12 Proebstle13 and Perkowski14 both proposed that the primary mechanism of action for 940 nm EVL was the formation of steam bubbles via delivery of laser energy, causing thermal injury to the vein endothelium, resulting in thrombotic occlusion. This mechanism was further defined by Proebstle et al18 using in vitro generation of steam bubbles with 810, 940 and 980-nm lasers. Each laser was examined in saline, plasma and hemolytic blood.18 None of the lasers were able to produce steam bubbles in saline or plasma alone, but did create perforations at sites of direct laser-tip contact.18 However, all lasers did produce steam bubbles in hemolytic blood, indicating that hemoglobin plays a key role in inflicting thermal damage to the vein wall.18 Original data from these studies helped to form the opinion that vein-wall perforations and extravasation of blood into surrounding tissues are the culprits in causing EVL post-operative pain and bruising.8 Procedurally, it is now largely accepted that the use of manual compression to achieve direct laser fiber-tip contact actually exacerbates the incidence of perforation and extravasation, and hence the incidence of pain and bruising.

Linear endovenous energy density (LEED). Subsequent to the steam-bubble mechanism of action premise, several researchers began to evaluate LEED for its effect on treatment outcomes. LEED is best defined as the number of joules delivered per centimeter of the target vein during an EVL procedure.17 Efficacy has been the primary endpoint of LEED studies, evaluating low LEED versus high LEED. In initial studies, Timperman et al3,4 determined that energy doses > 80 J/cm produced more efficacious results than LEED < 80 J/cm, with no difference in side effects. Similarly, another study concluded that LEED was the main determinant in the success of EVL, with the greatest efficacy occurring at an LEED > 60 J/cm.16 Pannier et al21 evaluated a 1470 nm laser, reporting a 100% success rate with an average LEED of 107 J/cm for great saphenous vein treatment. It was noted that in the limbs which received a LEED > 100 J/cm, there was a considerably higher incidence of paresthesia (15.5%) than limbs receiving < 100 J/cm (2.3%).21 The data from these studies suggest that the optimal LEED is in the range of 60 J/cm to 100 J/cm.3,4,16,21 LEED in these studies below the target range led to failure, whereas, high LEED demonstrated increased side effects.3,4,16,21

  • 1
  • 2
  • 3
  • 4
  • 5
  • next ›
  • last »
image description image description

Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.

  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Alex Dulnikowski, Classified Sales Manager
    (800) 237-7285, ext. 205

vdm Blogs

A New Algorithm to Treat Patients with Peripheral Vascular Disease

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT

In-Stent Restenosis in the SFA Remains a Significant Unresolved Problem

Frank J Criado MD FACS FSVM

Support Comes From Many Directions

Richard R. Heuser MD FACC FACP FESC FSCAI

Pedal Artery Access: Advances in Management of Critical limb ischemia

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT

The SFA School of Thought Continues

Lawrence A. Garcia MD
more »

Vascular Newswire

  • Vascular Solutions Launches Reprocessing Service For Closurefast Vein Catheters
    Fri, 02/03/12 - 1:14pm
  • AMA: Halt Implementation of ICD-10
    Thu, 02/02/12 - 11:56am
  • NHS Makes GBP200 Non-Drug Hypertension Treatment Device Available on Prescription
    Wed, 02/01/12 - 11:06am
  • AngioDynamics to Acquire Navilyst Medical
    Tue, 01/31/12 - 2:48pm
more »

Clinical Events Calendar

  • American Venous Forum 24th Annual Meeting
    Wed, 02/08/2012 - Sat, 02/11/2012
    Orlando, FL, United States
  • JIM 2012
    Thu, 02/09/2012 - Sat, 02/11/2012
    Rome, Italy
  • Cardiovascular Care Update 2012 (CVC)
    Fri, 02/10/2012 - Sat, 02/11/2012
    Scottsdale, AZ, United States
more »

Poll

Do you think that endostaples will soon become important tools in the hands of aortic interventionists?:
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2012 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2012 HMP Communications